FindTrial
Sign In

Effect of Vitamin D and turmeric in lymphoma patients.

Efficacy and safety of combination of cholecalciferol and Curcuma longa as an add-on therapy to standard R-CHOP in Diffuse Large B cell Lymphoma (DLBCL) - a randomized open label 2x2 factorial trial - E-SCHOLAR

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025818
Enrollment
80
Registered
2020-06-11
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C833- Diffuse large B-cell lymphoma

Interventions

Intervention1: Cholecalciferol (Vitamin D capsules) and Curcuma longa (Turmeric capsules): Oral Cholecalciferol 2000 IU once daily and Oral Curcuma longa 550 mg thrice daily with standard R-CHOP thera

Sponsors

JIPMER Intramural fund
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed patients of diffuse large B cell lymphoma (DLBCL) [based on the 2008 World Health Organization classification] to be started on R-CHOP with serum 25 hydroxy D level less than 30 ng/ml.

Exclusion criteria

Exclusion criteria: Subjects previously treated with chemotherapy except for prefix chemotherapy, radiotherapy, immunotherapy or experimental therapies for lymphoma or other malignancy. History of other cancer within the past 5 years except curatively treated non- melanoma skin cancer or in situ carcinoma of uterine cervix. Subjects diagnosed with double hit or triple hit lymphoma.

Design outcomes

Primary

MeasureTime frame
Event Free Survival at the end of two years (EFS24) of diagnosis in patients with DLBCLTimepoint: Two years—

Secondary

MeasureTime frame
Overall Survival (OS) at the end of three years of diagnosis in patients with DLBCLTimepoint: Three years—

Countries

India

Contacts

Public ContactDr Prasanth Ganesan

JIPMER

sandhiyaselvarajan@gmail.com9443492922

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026